Breast Cancer Research: New Targets, Novel Targeted Agents

Speaker: Nadia Harbeck

N. Harbeck provides an expert analysis from the PEGGY, DETECT and PALOMA 3 studies presented at ECC 2015. PEGGY study investigated a novel PI3K inhibitor pictilisib; DETECT association between HER2 on circulating tumour cells and primary breast tumour; and PALOMA 3 palbociclib, a selective inhibitor of the cyclin-dependent Kinases CDK4 and CDK6.

Discussion Points

Abstract #1803 from ECC 2015: PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer. What is a rationale for the study? What are the key study results?

Abstract #1805 from ECC 2015: Association between HER2-Phenotype on circulating tumor cells and primary tumor characteristics in women with metastatic breast cancer. What is a rationale for the study? What are the key study results? What is the impact for current practice?

Abstract #1815 from ECC 2015: A double blind phase III trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes. What is a rationale for the study? What are the key study results? What is the impact for current practice?